MedSina
Health library › Evidence-based

Tranexamic Acid Use for Bleeding Control in General Surgery

November 6, 2026·3 min read ·MedSina Evidence · PubMed

Discover how tranexamic acid helps manage perioperative bleeding in general surgery, reducing blood loss and transfusion needs safely.

Tranexamic Acid Use for Bleeding Control in General Surgery

Perioperative bleeding remains a significant challenge during surgical procedures, requiring careful management to maintain patient stability [1]. Uncontrolled bleeding and subsequent disruptions in the body's clotting system can complicate both surgical interventions and trauma care [2]. To address this, medical professionals often utilize pharmacological adjuncts to support hemostasis and protect patients from excessive blood loss.

Understanding Tranexamic Acid and Fibrinolysis

Tranexamic acid, commonly referred to as TXA, is a synthetic lysine analogue that has been utilized for decades to manage hemorrhagic conditions [2]. Under normal physiological conditions, the human body maintains a delicate balance between clot formation and fibrinolysis, the process that breaks down blood clots [2]. However, certain surgical procedures involving organs rich in plasminogen proactivators—such as the liver, kidneys, pancreas, and uterus—place patients at a heightened risk for hyperfibrinolysis, a state of excessive and systemic clot breakdown that can lead to severe, diffuse bleeding [2]. By acting as an antifibrinolytic agent, TXA helps stabilize blood clots, making it a valuable tool in both the prophylaxis and treatment of bleeding complications [2].

Efficacy in General Surgery and Noncardiac Procedures

Recent clinical investigations have sought to clarify the specific benefits and safety profiles of prophylactic TXA across various surgical settings. A comprehensive systematic review and meta-analysis published in 2026 evaluated numerous randomized clinical trials involving thousands of patients undergoing general surgery [1]. The findings demonstrated that prophylactic TXA administration is associated with a reduction in intraoperative blood loss and a lower requirement for blood transfusions [1]. Furthermore, large-scale clinical trials, such as the POISE-3 trial, have explored the efficacy of prophylactic TXA in noncardiac surgery for patients with elevated cardiovascular risk, indicating that it helps prevent major bleeding events without increasing vascular risks [4].

Targeted Applications and Endoscopic Uses

Beyond traditional open and laparoscopic procedures, antifibrinolytic therapy is also investigated in specialized gastroenterological interventions. Upper gastrointestinal bleeding, often caused by bleeding peptic ulcers or tumor-related sites, presents distinct clinical challenges due to the risk of rebleeding [6, 7]. Studies examining endoscopic therapies have explored the topical application of TXA directly onto bleeding ulcers or via endoscopic sprays, sometimes combined with protective barrier agents like sucralfate [5, 6, 7]. These targeted approaches aim to enhance local hemostasis and reduce early treatment failure or recurrent bleeding rates in vulnerable patient populations [6, 7].

Safety Profile and Considerations

When evaluating any perioperative medication, safety is a paramount concern for surgical and anesthetic teams. Clinical studies examining TXA use in general surgery and oncology populations generally report that the medication is well-tolerated with few adverse effects [1, 3]. While large-scale studies continue to monitor outcomes such as thromboembolic events and overall mortality, current evidence supports its role as an effective prophylactic option to minimize bleeding complications when properly administered under clinical guidance [1, 4].

Sources

tranexamic acidbleeding controlgeneral surgerysurgery

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.